Eine Studie zur Kombinationstherapie von Guselkumab und Golimumab bei Teilnehmern mit aktiver Psoriasis-Arthritis (AFFINITY)
Eine multizentrische, randomisierte Doppelblindstudie der Phase 2a zur Bewertung der Wirksamkeit und Sicherheit einer subkutan verabreichten Kombinationstherapie aus Guselkumab und Golimumab bei Teilnehmern mit aktiver Psoriasis-Arthritis
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Contact
- Telefonnummer: 844-434-4210
- E-Mail: Participate-In-This-Study@its.jnj.com
Studienorte
-
-
-
Frederiksberg, Dänemark, 2000
- Frederiksberg Hospital
-
Glostrup Municipality, Dänemark, 2600
- Rigshospitalet Glostrup
-
Køge, Dänemark, 4600
- Køge Sygehus Region Sjaelland
-
Silkeborg, Dänemark, 8600
- Silkeborg Hospital
-
Vejle, Dänemark, 7100
- Vejle Sygehus
-
-
-
-
-
Le Mans, Frankreich, 72037
- Centre Hospitalier Le Mans
-
Toulouse, Frankreich, 31059
- Hopital Larrey CHU de Toulouse
-
Tours, Frankreich, 37044
- CHU Trousseau - Service de Rhumatologie
-
-
-
-
-
Cagliari, Italien, 09124
- Azienda Ospedaliero-Universitaria di Cagliari
-
Milan, Italien, 20132
- Ospedale San Raffaele
-
Milan, Italien, 20122
- Centro Specialistico Ortopedico Traumatologico Gaetano Pini CTO
-
Pavia, Italien, 27100
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Reggio Emilia, Italien, 42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma, Italien, 00168
- Policlinico Universitario Agostino Gemelli
-
Roma, Italien, 00133
- A.O.U.Policlinico Tor Vergata
-
Rome, Italien, 00128
- Università Campus Biomedico di Roma
-
Torino, Italien, 10128
- AO Ordine Mauriziano
-
-
-
-
-
Elblag, Polen, 82-300
- Centrum Kliniczno Badawcze
-
Lodz, Polen, 90-242
- Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
-
Nadarzyn, Polen, 05-830
- NZOZ Lecznica MAK MED S C
-
Poznan, Polen, 61 113
- Centrum Medyczne
-
Warsaw, Polen, 00-874
- Medycyna Kliniczna
-
Warsaw, Polen, 03 291
- Centrum Medyczne AMED Targowek
-
Wroclaw, Polen, 51 685
- WroMedica I Bielicka A Strzalkowska s c
-
-
-
-
-
Kemerovo, Russland, 650000
- Kemerovo State Medical University
-
Kemerovo, Russland, 650070
- LLL Medical Center Revma-Med
-
Korolyov, Russland, 141060
- LLC Family Outpatient Clinic # 4
-
Moscow, Russland, 129110
- GBUZ of Moscow Region 'Moscow Region SRI n.a. Vladimirskyi'
-
Orenburg, Russland, 460000
- Orenburg State Medical Academy
-
Rostov-on-Don, Russland, 344007
- Rostov Regional Clinical Dermatovenerological Dispensary
-
Ryazan, Russland, 390046
- Ryazan Regional Clinical Dermatovenerological Dispensary
-
Saint Petersburg, Russland, 194156
- X7 Clinical Research Company Limited
-
Smolensk, Russland, 214025
- Smolensk regional hospital on Smolensk railway station
-
Ufa, Russland, 450005
- Republican Clinical Hospital - G.G. Kuvatov
-
Yaroslavl, Russland, 150007
- Clinical Hospital #3
-
-
-
-
-
Malmö, Schweden, 205 02
- Skånes universitetssjukhus
-
Solna, Schweden, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
A Coruña, Spanien, 15006
- Hosp Univ A Coruna
-
Barcelona, Spanien, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Bilbao, Spanien, 48013
- Hosp. Univ. de Basurto
-
Córdoba, Spanien, 14004
- Hosp Reina Sofia
-
Madrid, Spanien, 28041
- Hosp. Univ. 12 de Octubre
-
Sabadell, Spanien, 08208
- Corporacio Sanitari Parc Tauli
-
Santiago de Compostela, Spanien, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Spanien, 41009
- Hosp. Virgen Macarena
-
Seville, Spanien, 41014
- Hosp. Ntra. Sra. de Valme
-
Seville, Spanien, 41010
- Hosp. Infanta Luisa
-
-
-
-
-
Kharkiv, Ukraine, 61039
- State Institution Institute of therapy named after L.T.Malaya AMS Ukraine
-
Kharkiv, Ukraine, 61204
- Municipal Institution Regional hospital-center of emergency care and disasters medicine
-
Kyiv, Ukraine, 03049
- Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
-
Kyiv, Ukraine, 03680
- SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine
-
Kyiv, Ukraine, 03037
- Medical Research and Practice Center Medbud of the Public Joint Stock Holding Company Kyivmiskbud
-
Kyiv, Ukraine, 04107
- Municipal Non-Profit Enterprise of Kyiv Regional Council 'Kyiv regional Clinical Hospital'
-
Poltava, Ukraine, 36011
- ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
-
Ternopil, Ukraine, 46002
- Municipal institution of Tepnopil Regional Council 'Ternopil University Hospital'
-
Uzhhorod, Ukraine, 88000
- MNCE Zakarpatska Regional Clinical Hospital named after A Novak of Zakarpatska Regional Council
-
Vinnytsia, Ukraine, 21009
- Health Clinic Limited Liability Company
-
Zaporizhzhya, Ukraine, 69600
- Medical Center LLC 'Modern Clinic'
-
-
-
-
-
Budapest, Ungarn, 1036
- Obudai Egeszsegugyi Centrum Kft
-
Gyula, Ungarn, 5700
- Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
-
Székesfehérvár, Ungarn, 8000
- Complex Rendelo Med Zrt
-
Veszprém, Ungarn, 8200
- Vital Medical Center
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85032
- Arizona Arthritis and Rheumatology Research PLLC
-
Phoenix, Arizona, Vereinigte Staaten, 85037
- Arizona Arthritis and Rheumatology Research PLLC 1
-
-
Arkansas
-
Searcy, Arkansas, Vereinigte Staaten, 72143
- Unity Health-White County Medical Center
-
-
Florida
-
Avon Park, Florida, Vereinigte Staaten, 33825
- HARAC Research Corp
-
Bay Pines, Florida, Vereinigte Staaten, 33744
- Bay Pines VA Healthcare System
-
DeBary, Florida, Vereinigte Staaten, 32713
- Omega Research Consultants
-
Miami, Florida, Vereinigte Staaten, 33136
- South Coast Research Center
-
Ocoee, Florida, Vereinigte Staaten, 34761
- Advanced Clinical Research of Orlando
-
Ormond Beach, Florida, Vereinigte Staaten, 32174
- Millennium Research
-
-
Georgia
-
Marietta, Georgia, Vereinigte Staaten, 30060
- Atlanta Research Center for Rheumatology
-
-
Michigan
-
Lansing, Michigan, Vereinigte Staaten, 48911
- Great Lakes Center of Rheumatology
-
-
Missouri
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Clinvest
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten, 11201
- NYU Langone Ambulatory Care Brooklyn Heights
-
New York, New York, Vereinigte Staaten, 10016
- NYU School of Medicine
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
The Bronx, New York, Vereinigte Staaten, 10461
- Jacobi Medical Center
-
-
Ohio
-
Vandalia, Ohio, Vereinigte Staaten, 45377
- STAT Research, Inc.
-
-
Texas
-
Plano, Texas, Vereinigte Staaten, 75024
- Trinity Universal Research Associates, LLC
-
Tomball, Texas, Vereinigte Staaten, 77375
- DM Clinical Research
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98122
- Swedish Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Beschreibung
Einschlusskriterien:
- Eine Diagnose von Psoriasis-Arthritis (PsA) für mehr als oder gleich (>=) 6 Monate vor der ersten Verabreichung der Studienintervention haben und die Klassifizierungskriterien für PsA (CASPAR)-Kriterien beim Screening erfüllen
- Haben Sie eine aktive PsA, wie definiert durch mindestens 3 geschwollene Gelenke und mindestens 3 empfindliche Gelenke beim Screening und zu Studienbeginn
- Haben Sie mindestens 1 der folgenden PsA-Untergruppen: Beteiligung des distalen Interphalangealgelenks, polyartikuläre Arthritis ohne Rheumaknoten, Arthritis mutilans, asymmetrische periphere Arthritis oder Spondylitis mit peripherer Arthritis
- Haben Sie eine aktive Plaque-Psoriasis mit mindestens einer psoriatischen Plaque von >= 2 Zentimeter (cm) Durchmesser oder Nagelveränderungen, die mit Psoriasis übereinstimmen
- Haben Sie ein unzureichendes Ansprechen (IR) auf eine Therapie mit Anti-Tumornekrosefaktor-Alpha (Anti-TNF-Alpha), definiert als Vorhandensein von aktivem PsA trotz Behandlung mit entweder 1 oder 2 vorherigen Anti-TNF-Alpha-Mitteln und den folgenden : a. Kein Nutzen von entweder 1 oder 2 vorherigen Anti-TNF-alpha-Therapien, wie in der Anamnese des behandelnden Arztes dokumentiert, nach mindestens 12-wöchiger Etanercept-, Adalimumab- oder Certolizumab-Pegol-Therapie oder mindestens 14-wöchiger Infliximab-Therapie oder ein beliebiges Biosimilar dieser 4 Therapien. Ein dokumentierter fehlender Nutzen kann eine unzureichende Verbesserung der Anzahl der Gelenke, der körperlichen Funktion oder der Krankheitsaktivität umfassen; b. Die letzte Dosis der Anti-TNF-alpha-Therapie muss mehr als 5 Halbwertszeiten des Arzneimittels vor der ersten Verabreichung der Studienintervention (Washout-Periode) stattgefunden haben.
Ausschlusskriterien:
- Hat andere entzündliche Erkrankungen, die die Bewertung des Nutzens einer Guselkumab- und/oder Golimumab-Therapie verfälschen könnten, einschließlich, aber nicht beschränkt auf rheumatoide Arthritis (RA), ankylosierende Spondylitis (AS), nicht röntgenologische axiale Spondyloarthritis (nr AxSpA), systemischer Lupus erythematodes oder Lyme Krankheit
- Hat eine bekannte Intoleranz oder Überempfindlichkeit gegenüber biologischen Medikamenten oder bekannte Allergien oder klinisch signifikante Reaktionen auf murine, chimäre oder menschliche Proteine, monoklonale Antikörper (mAb) oder Antikörperfragmente
- Hat eine vorherige Behandlung mit Golimumab oder Guselkumab erhalten oder hat eine dokumentierte Unverträglichkeit gegenüber einer vorherigen Anti-TNF-alpha-Therapie in der Anamnese des behandelnden Arztes
- Hat mehr als 2 frühere Anti-TNF-alpha-Mittel (oder Biosimilars) erhalten
- Positiver Antikörpertest gegen das humane Immundefizienzvirus (HIV).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Gruppe 1: Guselkumab und Golimumab
Die Teilnehmer erhalten subkutan (SC) Guselkumab und Golimumab.
|
Guselkumab wird als SC-Injektion verabreicht.
Andere Namen:
Golimumab wird als SC-Injektion verabreicht.
Andere Namen:
|
|
Aktiver Komparator: Gruppe 2: Guselkumab und Placebo
Die Teilnehmer erhalten SC Guselkumab und Placebo.
|
Guselkumab wird als SC-Injektion verabreicht.
Andere Namen:
Placebo wird als SC-Injektion verabreicht.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24
Zeitfenster: Week 24
|
MDA was a measure that defines a satisfactory state of disease activity that includes 5 domains of psoriatic arthritis (PsA) (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis).
Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints) <=1, Swollen joint count (66 joints) <=1, Psoriasis activity and severity index (PASI) <=1, Patient's Assessment of Pain <=15 on a 100-unit visual analog scale (VAS), Patient's Global Assessment of Disease Activity (arthritis and psoriasis) <=20 on a 100-unit VAS, Disability Index of the Health Assessment Questionnaire (HAQ-DI) score <=0.5, and Tender entheseal points <= 1 (Leeds Enthesitis Index [LEI] score <= 1).
|
Week 24
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 24
Zeitfenster: Week 24
|
ACR 50 response was defined as greater than or equal to (>=) 50% improvement from baseline in both swollen joint (66 joints) and tender joint counts (68 joints) and >=50% improvement from baseline in >=3 of 5 assessments: Physician global assessment of disease activity (0 to 100 millimeters [mm] VAS [0=no arthritis activity and 100=extremely active arthritis]), Patient global assessment of disease activity (arthritis) (100 mm VAS [0 = no limitation of normal activities; 100 = very poor]), Patient's global assessment of pain (100 mm VAS [0 = no pain; 100 = most severe pain]), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and high-sensitivity C-reactive protein (hsCRP).
|
Week 24
|
|
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 16
Zeitfenster: Week 16
|
MDA was a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis).
Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints) <=1, Swollen joint count (66 joints) <=1, PASI <=1, Patient's Assessment of Pain <=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) <=20 on a 100-unit VAS, HAQ-DI score <=0.5, and Tender entheseal points <= 1 (LEI score <= 1).
|
Week 16
|
|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among Participants With >= 3% Body Surface Area (BSA) Psoriatic Involvement and an Investigator Global Assessment (IGA) Score of >=2 (Mild) at Baseline
Zeitfenster: Week 24
|
PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy.
In the PASI system, the body was divided into 4 regions: head and neck, trunk (including axillae and groin), upper extremities, and lower extremities (included buttocks).
Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 to 100% involvement), and erythema, induration and scaling, each rated on a scale of 0 to 4, that was none to maximum severity.
PASI produces a numeric score range from 0 (no psoriasis) to 72 (worst condition).
Higher scores indicated more severe disease.
|
Week 24
|
|
Percentage of Participants Who Achieved PASI 100 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Zeitfenster: Week 24
|
PASI 100 response was defined as 100% reduction in PASI relative to baseline.
PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy.
In the PASI system, the body was divided into 4 regions: head and neck, trunk (including axillae and groin), upper extremities, and lower extremities (included buttocks).
Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 to 100% involvement), and erythema, induration and scaling, each rated on a scale of 0 to 4, that was none to maximum severity.
PASI produces a numeric score range from 0 (no psoriasis) to 72 (worst condition).
Higher scores indicated more severe disease.
|
Week 24
|
|
Percentage of Participants With an IGA-psoriasis Response at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Zeitfenster: Week 24
|
IGA psoriasis response was defined as an IGA psoriasis score of 0 (cleared) or 1 (minimal) and >=2 grade reduction from baseline in the IGA psoriasis score.
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point.
Overall lesions were graded for induration, erythema, and scaling each using a 5 point scale: clear (0), minimal (1), mild (2), moderate (3), and severe (4).
The IGA score of psoriasis was based upon the average of induration, erythema, and scaling scores.
The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
|
Week 24
|
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24
Zeitfenster: Baseline (Week 0), Week 24
|
Change from baseline in HAQ-DI score was a measure of the change in the physical function.
It consists of a 20-questions instrument that assesses the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living).
Responses in each functional area were scored from 0 = no difficulty to 3= inability to perform a task.
Scores on each task were summed and averaged to provide an overall HAQ-DI total score ranging from 0 (least difficulty) to 3 (extreme difficulty).
Lower scores indicated better functioning.
Negative change from baseline indicated improvement of physical function.
|
Baseline (Week 0), Week 24
|
|
Percentage of Participants Who Had Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline
Zeitfenster: Week 24
|
Enthesitis assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of tenderness by applying local pressure to the following enthesis sites: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion.
Each site was scored as 1 if tenderness was present or 0 if tenderness was absent.
The enthesitis index score was a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Higher score indicated more sites with tenderness.
A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI >0.
|
Week 24
|
|
Percentage of Participants Who Achieved Resolution of Dactylitis Response at Week 24 Among the Participants With Dactylitis at Baseline
Zeitfenster: Week 24
|
Dactylitis was characterized by swelling in both hands and feet.
The severity of dactylitis was scored on a scale from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit.
The results for each digit summed to produce final dactylitis score which was from 0 to 60. Higher score indicates more severe dactylitis.
Dactylitis count was derived based on dactylitis score, each score was recorded to 0 or 1 from 0 to 3, where any score >0 was recorded as 1.
For resolution of dactylitis, it was defined as participants who had a dactylitis score greater than 0 at baseline and a score of 0 at the analysis visit.
|
Week 24
|
|
Change From Baseline in Short Form Health Survey (SF-36) Physical Component Score (PCS) at Week 24
Zeitfenster: Baseline (Week 0), Week 24
|
SF-36 was a multi-domain instrument with 36 items to evaluate health status and quality of life.
It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health).
The scores for the 8 domains were combined into two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score.
Domains 1 to 4 primarily contribute to the PCS score of the SF-36.
Domains 5-8 primarily contributes to the MCS score of the SF-36.
Each of the 8 domain scores and the component summary score ranged from 0=worst to 100=best.
Higher scores represent better health status.
A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
|
Baseline (Week 0), Week 24
|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: From Week 0 up to Week 36
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
TEAEs were any AE occurred at or after the initial administration of study intervention through the day of last dose plus 16 weeks.
|
From Week 0 up to Week 36
|
|
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Zeitfenster: From Week 0 up to Week 36
|
SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event.
TESAEs were any SAE occurred at or after the initial administration of study intervention through the day of last dose plus 16 weeks.
|
From Week 0 up to Week 36
|
|
Percentage of Participants With Reasonably Related Adverse Events (AEs)
Zeitfenster: From Week 0 up to Week 36
|
Percentage of participants with reasonably related AEs was reported.
An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
AE reasonably related to guselkumab or golimumab were defined as AEs classified by the investigator as related to study agent.
|
From Week 0 up to Week 36
|
|
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention
Zeitfenster: From Week 0 to Week 20
|
Percentage of participants with AEs leading to discontinuation of study intervention was reported.
AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
|
From Week 0 to Week 20
|
|
Percentage of Participants With Infections
Zeitfenster: From Week 0 up to Week 36
|
Percentage of participants with infections was reported.
Investigators evaluate participants for any signs or symptoms of infection.
An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
|
From Week 0 up to Week 36
|
|
Percentage of Participants With Injection-site Reactions
Zeitfenster: From Week 0 up to Week 36
|
Percentage of participants with injection-site reaction was reported.
A study intervention injection-site reaction was any adverse reaction at a subcutaneous study intervention injection-site.
The injection sites were evaluated for reactions, and any injection-site reaction was recorded as an AE.
Injection site reactions were significant bruising, erythema, hemorrhage, irritation, pain, and pruritus.
|
From Week 0 up to Week 36
|
|
Group 1: Guselkumab Plus Golimumab - Serum Concentration of Golimumab
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, 24, and 36
|
Serum concentration of golimumab was reported.
|
Weeks 0, 4, 8, 12, 16, 20, 24, and 36
|
|
Serum Concentration of Guselkumab
Zeitfenster: Weeks 0, 4, 8, 12, 16, 20, 24, and 36
|
Serum concentration of guselkumab was reported.
|
Weeks 0, 4, 8, 12, 16, 20, 24, and 36
|
|
Percentage of Participants With Anti-Guselkumab Antibodies
Zeitfenster: From Week 0 up to Week 36
|
Percentage of participants with anti-guselkumab antibodies was reported.
|
From Week 0 up to Week 36
|
|
Percentage of Participants With Anti-Golimumab Antibodies
Zeitfenster: From Week 0 up to Week 36
|
Percentage of participants with anti-golimumab antibodies were reported.
|
From Week 0 up to Week 36
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Knochenerkrankungen
- Erkrankungen des Bewegungsapparates
- Arthritis
- Gelenkerkrankungen
- Erkrankungen der Wirbelsäule
- Spondylarthropathien
- Hautkrankheiten, papulosquamös
- Hautkrankheiten
- Spondylarthritis
- Spondylitis
- Schuppenflechte
- Haut- und Bindegewebserkrankungen
- Arthritis, Psoriasis
- Tumor-Nekrose-Faktor-Inhibitoren
- Immunsuppressive Mittel
- Immunologische Faktoren
- Physiologische Wirkungen von Arzneimitteln
- Entzündungshemmende Mittel
- Guselkumab
- Golimumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CR109054
- 2021-002012-31 (EudraCT-Nummer)
- CNTO1959PSA2003 (Andere Kennung: Janssen Research & Development, LLC)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .